HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for BriaCell Therapeutics, maintaining a price target of $18.
September 11, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for BriaCell Therapeutics, maintaining a price target of $18, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target at $18 by a reputable analyst suggests positive sentiment and potential upside for BriaCell Therapeutics, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100